I believe that $AKBA is more likely than not to receive another CRL for Vadadustat, and that vol is severely mispriced, with the stock having immense downside risk. The PDUFA date is March 27th. AKBA's prior CRL highlighted two safety issues in dialysis patients leading to poor benefit/risk, stating that the company could explore ways to demonstrate a more favorable risk/benefit through new clinical trials.

$IOVA A not-so-brief history of BLA guidance through press releases. In fairly lengthy thread form because there are THAT many. Seems outrageous that this company is still legitimately entertained as an investment by anyone, to the tune of a nearly $2B market cap no less.